ArticleOncotarget2018

Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model.

Kentaro Igarashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.